Effect of ginsenoside on fine particulate matter induced oxidative injury in human endothelial cells.
- Author:
Gui-jin MA
1
;
Ji-yuan LÜ
;
Ming-sheng ZHANG
;
Cai-ping LI
;
Gang QIN
Author Information
- Publication Type:Journal Article
- MeSH: Cells, Cultured; Ginsenosides; pharmacology; Heme Oxygenase-1; metabolism; Human Umbilical Vein Endothelial Cells; drug effects; metabolism; Humans; NF-E2-Related Factor 2; metabolism; Oxidative Stress; drug effects; Particulate Matter; toxicity
- From: Chinese Journal of Cardiology 2012;40(10):864-868
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the mechanism of fine particulate matter (PM(2.5)) induced endothelial injury and the efficacy and mechanism of ginsenoside Rg1 on the inhibition of endothelium injuries in human endothelial cells exposure to PM(2.5).
METHODSHuman umbilical vein endothelial cells (HUVECs) were stimulated with various concentrations PM(2.5) (0.1, 0.2, 0.4, 0.8 mg/ml) and PM(2.5) at concentration 0.8 mg/ml induced significant endothelial injury and was chosen for the main study in the presence or absence of Rg1 (0.04 mg/ml). After 24 h treatment, cell growth A value was detected through MTT, intracellular reactive oxygen species (ROS) level through fluorescence labeling probe method and HO-1, Nrf2 mRNA expression was detected by RT-PCR.
RESULTSThe cell A value was significantly lower while the ROS fluorescence gray value and the average optical density ratio of HO-1 were significantly higher in PM(2.5) group than in the control group (all P < 0.05). The average optical density ratio of Nrf2 was similar between PM(2.5) group and control group (P > 0.05). The A value and the average optical density ratio of HO-1 were significantly higher while the ROS fluorescence gray value was significantly lower in co-treated PM(2.5) (0.8 mg/ml) + Rg1 (0.04 mg/ml) group than in the PM(2.5) (0.8 mg/ml) group (all P < 0.05).
CONCLUSIONPM(2.5) could induce human endothelial cells injury by increasing oxidative stress which could be attenuated by ginsenoside Rg1.